ALN-TTRsc for the treatment of transthyretin in mediated amyloidosis and ALN-PCS02 for treating hypercholesterolemia is currently in clinical trial by Alnylam Pharmaceuticals [139]. This evidence concerns the gene ARLN and familial hypercholesterolemia.